Valerio Therapeutics chooses The HIVE to accelerate its R&D

Valerio Therapeutics develops innovative therapies. Its proprietary V‑Body platform, based on highly targeted, very small‑sized antibodies, enables the design of more precise treatments for complex pathologies.
The company focuses on developing drug candidates with the objective of generating an internal pipeline, paving the way for industrial partnerships, co‑development agreements, or licensing deals with biopharmaceutical players.

Today, Valerio counts a team of over 35 employees and is supported by recognised investors, including Artal International CSA.

A strategic foothold within a world‑class scientific ecosystem

Located on the Campus Grand Parc, just a short distance from the Villejuif – Gustave Roussy metro station (lines 14 and 15), The Hive acts as the “coffee machine” of the world‑leading oncology innovation ecosystem driven by the PSCC, bringing together academic, clinical, and industrial research.

An iconic 25,000 m² building, The Hive has been designed to host state‑of‑the‑art laboratories and flexible office spaces, offering an ideal environment to house, structure, and connect the players of this innovation community.

By joining The HIVE, Valerio Therapeutics is accelerating the structuring of its research activities.

“The installation of Valerio Therapeutics within The Hive by Kadans, at the heart of the Paris‑Saclay Cancer Cluster in Villejuif, marks an important milestone in our strategic repositioning. Initiated at the end of 2024, the first restructuring phase enabled us to stabilise the company both economically and strategically, by refocusing our activities on our two technology platforms — the bioconjugate chemistry of therapeutic oligonucleotides ‘Oligo‑link’ and the single‑domain antibodies ‘V‑Body’. We are now entering a second phase, aimed at re‑anchoring within the French scientific ecosystem. The proximity to Gustave Roussy, to the innovative biotechs of the cluster, and to CRO partners creates a particularly stimulating environment. We are convinced that this dynamic will foster strong scientific and operational synergies, accelerating our programmes.” explain Julien Miara, CEO of Valerio Therapeutics

“We are delighted to welcome Valerio Therapeutics to The Hive,”
declares Elsa FERRARD, France Director at Kadans Science Partner.
“Their expertise in precision therapeutic targeting technologies further enriches the Campus Grand Parc ecosystem and illustrates the attractiveness of The HIVE for innovative biotechnology companies, particularly in oncology.”